Considerations for Treatment Decision Making for Advanced Renal Cell Carcinoma

Video

Sumeet Bhatia, MD, explains the factors he considers in choosing a treatment for advanced renal cell carcinoma and the role biomarkers have in the process.

Eric Jonasch, MD: Dr Bhatia, what factors do you take into consideration when choosing among the available treatment options? Do you look at patient age, comorbidities, or prognostic features? What other factors do you use when you choose 1 of these regimens?

Sumeet Bhatia, MD: Any patient who walks into our clinic, the first thing we do is try to determine the IMDC [International Metastatic Renal Cell Carcinoma Database Consortium] risk stratification, which takes into account the performance status, time to diagnosis, the hemoglobin, calcium, neutrophil count, and platelet count. We put them into 3 broad categories. Those with 0 risk factors have a wide range of options for them. For those who have more than 1 risk factor, we look at the performance status and try to decide the most appropriate regimen. The presence of hematuria, as well as brain metastases, does play into our decision-making. We also radiographically try to evaluate if by nephrectomy we can get rid of more than 95% of the bulk of the tumor and, based on that, decide what the most appropriate treatment options would be.

Eric Jonasch, MD: Do you use biomarkers for your treatment of patients with renal cell carcinoma? Are you guiding any of your therapy with either molecular or other markers?

Sumeet Bhatia, MD: No. For up-front therapy, we don’t depend on biomarkers. Metastatic kidney cancer seems to have become the first, probably the only, condition in which I don’t wait for next-generation sequencing, which we obtain through Tempus [DNA cancer testing] to guide our therapy. Clearly, if somebody has a history of 1 hemolytic disease, with the new drugs available, it may be different. As a matter of fact, in our practice, usually on first relapse you always have next-generation sequencing available. But I still struggle with how to use it and incorporate it in our clinical practice. The major purpose of having that is to guide patients’ enrollment into clinical trials. But it doesn’t change our standard clinical practice in first- or second-line therapy. How about you, Dr Jonasch?

Eric Jonasch, MD: I agree. We’re probably 5 or 10 years behind breast cancer and lung cancer with regard to that. We’ve identified what I would call secondary mutations. VHL mutations seem to be an obligate finding, or at least VHL dysfunction in clear cell. The SETD2, BAP1, PBRM1 mutations are defining how they influence the behavior of the tumors, but we haven’t assigned specific treatment regimens to those.

Transcript edited for clarity.

Related Videos
Samer A. Srour, MB ChB, MS
Nizar M. Tannir, MD, FACP, professor; Ransom Horne, Jr. Professor for Cancer Research, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Samer A. Srour, MB ChB, MS
Samer A. Srour, MB ChB, MS
Petros Grivas, MD, PhD, professor, Clinical Research Division, Fred Hutchinson Cancer Center; professor, Division of Hematology and Oncology, University of Washington (UW) School of Medicine; clinical director, Genitourinary Cancers Program, UW Medicine
A panel of 5 experts on renal cell carcinoma
Chandler H. Park, MD, an expert on renal cell carcinoma
Benjamin Garmezy, MD
Samer A. Srour, MB ChB, MS
Wenxin (Vincent) Xu, MD,
Related Content
Paul V. Viscuse, MD, of the University of Virginia

Applying ASCO GU 2024 Data to Clinical Practice in Bladder, RCC Care

April 22nd 2024
Article
Neal Shore, MD, FACS

FDA Approval Insights: Nadofaragene Firadenovec in BCG-Unresponsive NMIBC

January 26th 2023
Podcast
Professor Jun Guo, MD, PhD, from Peking University Cancer Hospital

Toripalimab Plus Axitinib Approved in China for Frontline Renal Cell Carcinoma

April 9th 2024
Article
Kyle A. Blum, MD, MS

Blum Highlights Implications of CA-125 Levels in Renal Medullary Carcinoma

December 19th 2022
Podcast
Shankar Siva, PhD, MBBS, FRANZCR, Peter MacCallum Cancer Centre

SABR Leads to Local Control in Primary RCC Without Surgery

April 3rd 2024
Article
John McGrane, MD, consultant oncologist, Royal Cornwall Hospitals NHS Trust

NICE Endorses Cabozantinib Plus Nivolumab in Advanced RCC

April 2nd 2024
Article